Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase
chronic myeloid leukemia
nephrotic syndrome
renal adverse effect
renal artery stenosis
tyrosine kinase inhibitor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Mar 2023
29 Mar 2023
Historique:
received:
20
02
2023
revised:
21
03
2023
accepted:
24
03
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Alongside their BCR-ABL specificity, TKIs used in chronic myeloid leukemia also target other tyrosine kinases expressed in the kidney such as PDGFR, c-KIT, SRC, and VEGFR, which may result in specific renal adverse drug reaction (ADR). To evaluate the renal safety profile in real-life conditions, a case/non-case study was performed on VigiBase From 7 November 2001 to 2 June 2021, all cases in which the involvement of imatinib, dasatinib, nilotinib, bosutinib, and ponatinib was suspected in the occurrence of renal ADR were extracted from VigiBase A total of 1409 cases were included. Imatinib accounts for half of the reported cases. A signal of disproportionate reporting (SDR) of renal failure and fluid retention was found for the five TKIs. Only dasatinib and nilotinib were related to an SDR for nephrotic syndrome. Nilotinib and ponatinib were related to an SDR for renal artery stenosis, while dasatinib was related to an SDR for thrombotic microangiopathy. No SDR for tubulointerstitial nephritis was observed. This study identified a new safety signal, nephrotic syndrome, for nilotinib and highlights the importance of post-marketing safety surveillance.
Sections du résumé
BACKGROUND
BACKGROUND
Alongside their BCR-ABL specificity, TKIs used in chronic myeloid leukemia also target other tyrosine kinases expressed in the kidney such as PDGFR, c-KIT, SRC, and VEGFR, which may result in specific renal adverse drug reaction (ADR). To evaluate the renal safety profile in real-life conditions, a case/non-case study was performed on VigiBase
METHODS
METHODS
From 7 November 2001 to 2 June 2021, all cases in which the involvement of imatinib, dasatinib, nilotinib, bosutinib, and ponatinib was suspected in the occurrence of renal ADR were extracted from VigiBase
RESULTS
RESULTS
A total of 1409 cases were included. Imatinib accounts for half of the reported cases. A signal of disproportionate reporting (SDR) of renal failure and fluid retention was found for the five TKIs. Only dasatinib and nilotinib were related to an SDR for nephrotic syndrome. Nilotinib and ponatinib were related to an SDR for renal artery stenosis, while dasatinib was related to an SDR for thrombotic microangiopathy. No SDR for tubulointerstitial nephritis was observed.
CONCLUSION
CONCLUSIONS
This study identified a new safety signal, nephrotic syndrome, for nilotinib and highlights the importance of post-marketing safety surveillance.
Identifiants
pubmed: 37046701
pii: cancers15072041
doi: 10.3390/cancers15072041
pmc: PMC10093506
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51
pubmed: 28881915
J Eval Clin Pract. 2014 Oct;20(5):559-69
pubmed: 24909067
Leuk Lymphoma. 2016;57(3):726-7
pubmed: 26436329
Ren Fail. 2010 Jan;32(1):147-9
pubmed: 20113282
Medicine (Baltimore). 2014 Nov;93(24):333-339
pubmed: 25500702
Am J Pathol. 2003 Jul;163(1):277-86
pubmed: 12819032
Curr Biol. 2003 Aug 19;13(16):1442-50
pubmed: 12932330
Haematologica. 2014 Jul;99(7):1197-203
pubmed: 24658819
Leuk Res. 2010 Jan;34(1):123-7
pubmed: 19640584
J Am Soc Nephrol. 2008 Jan;19(1):12-23
pubmed: 18077793
Diagnostics (Basel). 2021 Apr 01;11(4):
pubmed: 33916159
Therapie. 2018 May - Jun;73(3):247-255
pubmed: 29174397
Ther Clin Risk Manag. 2017 Sep 11;13:1195-1203
pubmed: 28979130
Nephrol Dial Transplant. 2015 Sep;30(9):1449-55
pubmed: 25480873
Am J Pathol. 1999 Nov;155(5):1689-99
pubmed: 10550325
J Clin Oncol. 2007 Sep 1;25(25):3908-14
pubmed: 17761974
Drug Saf. 2015 Jun;38(6):577-87
pubmed: 25899605
Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):3-10
pubmed: 33275447
Br J Clin Pharmacol. 2011 Dec;72(6):905-8
pubmed: 21658092
J Am Soc Nephrol. 2018 May;29(5):1383-1396
pubmed: 29444905
Am J Kidney Dis. 2013 Jun;61(6):1026-31
pubmed: 23540262
J Clin Pharm Ther. 2014 Feb;39(1):102-5
pubmed: 24188312
Br J Clin Pharmacol. 2018 Oct;84(10):2373-2383
pubmed: 29943846
Therapie. 2022 Mar-Apr;77(2):207-217
pubmed: 34895753
Drug Saf. 2014 Apr;37(4):249-58
pubmed: 24627310
Am J Hematol. 2016 Jun;91(6):606-16
pubmed: 26971533
Thromb Res. 2015 Jan;135(1):155-60
pubmed: 25527332
Front Cardiovasc Med. 2018 Jun 12;5:55
pubmed: 29946549
Cancers (Basel). 2020 Mar 30;12(4):
pubmed: 32235443
Nat Commun. 2019 May 3;10(1):2061
pubmed: 31053734
Drug Saf. 1997 Jun;16(6):355-65
pubmed: 9241490
J Am Soc Nephrol. 2019 Feb;30(2):187-200
pubmed: 30642877
Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):427-36
pubmed: 19358225
J Hematol Oncol. 2009 Nov 12;2:46
pubmed: 19909541